We provide evidence that CIM7 functions via a unique mechanism compared to established RARα agonists and does not affect CMA in non-tumorigenic cells or activate macroautophagy in NSCLC, thus conferring its selectivity for both CMA and as a specific anti-cancer therapeutic. The gene discussed is RARA; the disease is cancer.